Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine

• Status: Completed
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is investigating the effect of sustained-release guanfacine (Intuniv) on language-based learning skills in children age 6-12 who are diagnosed with attention deficit hyperactivity disorder (ADHD).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Neurology Group of Bergen County, P.A.
• Collaborator: Shire
• Treatments: Guanfacine

Criteria

Inclusion Criteria: Diagnosis of ADHD-inattentive or combined type.

Exclusion Criteria:

• Intelligence (IQ) below 85 as determined by formal testing.

• Identified or suspected genetic syndromes.

• Autism or other pervasive developmental disorders.

• Psychiatric disorders other than ADHD and oppositional defiant disorder.

• Heart, liver or renal disease.

• Cancer.

• Epilepsy or non-febrile seizure history.

• Cardiac arrhythmia, bradycardia, or syncope.

• Any other condition considered to be potentially exacerbated or endangered by treatment with an alpha-2 agonist drug.